title: Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
abstract: Mutations in the KCNJ11 gene, which encodes the Kir6.2 subunit of the ATP-sensitive potassium channel, often result in neonatal diabetes. Patients with this mutation have been successfully transitioned from insulin to sulfonylurea (SU) therapy without compromise in their glycemic control. Among patients with neonatal diabetes due to KCNJ11 mutations, approximately 25% have neurological findings including developmental delay, motor dysfunction, and epilepsy, known as DEND syndrome. There have been rare cases of juvenile patients with intermediate DEND syndrome (iDEND) reporting variable improvement in neurological function following transition from insulin to SU treatment. We describe the response to glyburide in a 15-yr-old boy with severe global developmental delays resulting from the KCNJ11 mutation V59M. The patient was discovered to have diabetes mellitus at 11.5 months of age, making this the oldest age at diagnosis of a KCNJ11 mutation-related case of neonatal diabetes. Because consensus has been to screen patients for this mutation only if younger than 6 months at the time of diagnosis, we suggest that all patients under the age of 12 months at diagnosis should receive genetic testing for monogenic causes of diabetes.
authors.affiliation: Division of Pediatric Endocrinology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA. amohama1@jhmi.edu
authors.forename: Ali
authors.initials: A
authors.lastname: Mohamadi
authors.forename: Loretta M
authors.initials: LM
authors.lastname: Clark
authors.forename: Paul H
authors.initials: PH
authors.lastname: Lipkin
authors.forename: E Mark
authors.initials: EM
authors.lastname: Mahone
authors.forename: Ericka L
authors.initials: EL
authors.lastname: Wodka
authors.forename: Leslie P
authors.initials: LP
authors.lastname: Plotnick
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D003266:Continuity of Patient Care; D002658:Developmental Disabilities / Q000150:complications / Q000188:drug therapy*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000151:congenital* / Q000188:drug therapy*; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy*; D005905:Glyburide / Q000008:administration & dosage*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007231:Infant, Newborn; D055104:Infusions, Subcutaneous; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics*; D013577:Syndrome; D028761:Withholding Treatment; D000099161:Kcnj11 Channel
chemical_list: D005905:Glyburide; D007004:Hypoglycemic Agents; D007328:Insulin; D024661:Potassium Channels, Inwardly Rectifying; D000099161:Kcnj11 Channel